Therefore, we aimed to investigate the renal molecular actions of the sGC activator cinaciguat in streptozotocin-induced type-1 diabetic rats, focusing on glomerular and podocyte damage, glomerular cGMP levels, apoptosis, cell proliferation, profibrotic signaling (TGF-ß1 CTGF, ERK1/2) and MMP/TIMP imbalance. The gene discussed is MAPK3; the disease is type 1 diabetes mellitus.